title: Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
abstract: Breast cancer is the most common tumor in women with Li-Fraumeni Syndrome (LFS), an inherited cancer syndrome associated with germline mutations in the TP53 tumor suppressor gene. Their lifetime breast cancer risk is 49% by age 60. Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series. We seek to complement the existing small literature with this report of a histopathologic analysis of breast cancers from women with documented LFS. Unstained slides and paraffin-embedded tumor blocks from breast cancers from 39 germline TP53 mutation carriers were assembled from investigators in the LFS consortium. Central histology review was performed on 93% of the specimens by a single breast pathologist from a major university hospital. Histology, grade, and hormone receptor status were assessed by immunohistochemistry; HER-2 status was defined by immunohistochemistry and/or FISH. The 43 tumors from 39 women comprise 32 invasive ductal carcinomas and 11 ductal carcinomas in situ (DCIS). No other histologies were observed. The median age at diagnosis was 32 years (range 22-46). Of the invasive cancers, 84% were positive for ER and/or PR; and 81% were high grade. Sixty three percent of invasive and 73% of in situ carcinomas were positive for Her2/neu (IHC 3+ or FISH amplified). Of the invasive tumors, 53% were positive for both ER and HER2+; other ER/PR/HER2 combinations were observed. The DCIS were positive for ER and HER2 in 27% of the cases. This report of the phenotype of breast cancers from women with LFS nearly doubles the literature on this topic. Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive. These findings suggest that modern treatments may result in improved outcomes for women with LFS-associated breast cancer.
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue-D1123, Boston, MA 02215, USA.
authors.forename: Serena
authors.initials: S
authors.lastname: Masciari
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Dillon
authors.forename: Michelle
authors.initials: M
authors.lastname: Rath
authors.forename: Mark
authors.initials: M
authors.lastname: Robson
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Weitzel
authors.forename: Judith
authors.initials: J
authors.lastname: Balmana
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Gruber
authors.forename: James M
authors.initials: JM
authors.lastname: Ford
authors.forename: David
authors.initials: D
authors.lastname: Euhus
authors.forename: Alexandra
authors.initials: A
authors.lastname: Lebensohn
authors.forename: Melinda
authors.initials: M
authors.lastname: Telli
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Pochebit
authors.forename: Georgios
authors.initials: G
authors.lastname: Lypas
authors.forename: Judy E
authors.initials: JE
authors.lastname: Garber
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000150:complications / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D016158:Genes, p53; D018095:Germ-Line Mutation; D006801:Humans; D007150:Immunohistochemistry; D016864:Li-Fraumeni Syndrome / Q000150:complications* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D010641:Phenotype; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen